Talk:WuXi AppTec

More information WikiProject Companies To-do: ...

This article is rated Start-class on Wikipedia's content assessment scale.
It is of interest to the following WikiProjects:

Companies Low‑importance

This article is within the scope of WikiProject Companies, a collaborative effort to improve the coverage of companies on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.CompaniesWikipedia:WikiProject CompaniesTemplate:WikiProject Companiescompany

Low This article has been rated as Low-importance on the project's importance scale.

WikiProject Companies To-do:

Here are some tasks awaiting attention:

Article requests : Wikipedia:Requested articles/Business and economics/Companies
Assess : Category:Unassessed company articles
Copyedit : Category:Company articles needing attention
Infobox : Category:Company articles needing infoboxes
Maintain : Portal:Companies
Stubs : Help expand stub articles located at Category:Company stubs
Other :
- Tag company articles with the {{portal|Companies}} template
- Tag company talk pages with the {{WikiProject Companies}} project banner
- Answer requests for comments

The Wikimedia Foundation's Terms of Use require that editors disclose their "employer, client, and affiliation" with respect to any paid contribution; see WP:PAID. For advice about reviewing paid contributions, see WP:COIRESPONSE.

AM WuXi (talk · contribs) has been paid by WuXi AppTec on their behalf.

Hi, I would like to suggest some updates to the article based on the company's activities in recent years. Please add:

In the History section - In 2019, WuXi AppTec acquired Pharmapace, a clinical services company in San Diego, expanding WuXi AppTec's drug development and biometrics capabilities.^[1] In 2021, WuXi STA purchased a Bristol Myers Squibb drug product manufacturing facility in Switzerland, adding to WuXi STA's global services.^[2] The same year, WuXi AppTec acquired the UK-based R&D contract company, OXGENE, and created WuXi ATU, a CDMO subsidiary focusing on cell therapy and gene therapy.^[3] WuXi ATU opened a testing center in Philadelphia.^[4] In 2022, the WuXi STA Changzhou production campus initiated oligonucleotide and peptide manufacturing to expand cell and gene therapy advancements.^[5]

Additionally, the different WuXi AppTec entities are inaccurate in the article. See this source to explain the rename and the correct entities under the WuXi AppTec umbrella. As far as I understand, based on the guidelines, this would be an uncontroversial edit for me to do. As it is a bit labor-intensive, I am happy to go in and do it myself with the community's approval.

References

[1]
Adams, Ben (8 May 2019). "China's WuXi AppTec buys up U.S. Pharmapace, boosting biometrics offering". fiercebiotech.com.
[2]
"WuXi STA completes acquisition of Bristol Myers Squibb manufacturing facility in Switzerland". 3 August 2021.
[3]
"OXGENE Eyes Further Growth in Cell and Gene Therapy Services after Acquisition by WuXi AppTec". genedgenews.com. 3 March 2021.
[4]
MacDonald, Gareth (7 December 2021). "WuXi ATU opens cell and gene therapy testing center". bioprocessintl.com.
[5]
Keenan, Joseph (7 July 2022). "WuXi unveils new production capabilities at Changzhou campus amid expansion push". fiercepharma.com.

Thank you! AM WuXi (talk) 18:51, 3 January 2024 (UTC)

(copied in part from the talk-page of User:Drbogdan):

@AM WuXi: (and others) - Thank You for your comments - and requests - at first glance, your suggested edts seem ok - others may like to comment as well of course - hope this helps in some way - iac - Stay Safe and Healthy !! - Drbogdan (talk) 13:47, 12 January 2024 (UTC)

Drbogdan, thanks for chiming in! I appreciate all feedback from the community. I posted this request several weeks ago in an effort to update and improve the existing article. If you're comfortable with it, I'd appreciate you implementing the updates. Thank you! AM WuXi (talk) 19:05, 16 January 2024 (UTC)

@AM WuXi: (and others) - Thank You for your comments - and suggetions - I'd feel more comfortable with comments by other Editors - in order to develop a WP:CONSENSUS about this - Comments Welcome from other Editors of course - in any case - Stay Safe and Healthy - Drbogdan (talk) 21:02, 16 January 2024 (UTC)

Updates to the article

Related Articles